Ribociclib for Treating HR-Positive, HER2-Negative Early and Advanced Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Ribociclib in the Treatment of Hormone-Receptor Positive/HER2-Negative Advanced and Early Breast Cancer: Overview of Clinical Data and Patients Selection
Breast Cancer (Dove Med Press) 2022 Apr 01;14(2022)101-111, MC Parati, R Pedersini, G Perego, R Reduzzi, T Savio, M Cabiddu, K Borgonovo, M Ghilardi, A Luciani, F PetrelliFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.